Maternal whole blood mRNA signatures identify women at risk of early preeclampsia: a longitudinal study.
Adi Laurentiu TarcaRoberto RomeroOffer ErezDereje W GudichaNandor Gabor ThanNeta Benshalom-TiroshPercy PacoraChaur-Dong HsuTinnakorn ChaiworapongsaSonia S HassanNardhy Gomez-LopezPublished in: The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2020)
Circulating early transcriptomic markers for preeclampsia can be found either by untargeted profiling of the cellular transcriptome or by focusing on placental cell-specific mRNAs. The untargeted cellular mRNA signature was consistently increased in early preeclampsia after 22 weeks of gestation, and individual mRNAs of this signature were significantly increased as early as 11-17 weeks of gestation. Several single-cell placental signatures predicted future development of the disease at 11-17 weeks and were also increased in women already diagnosed at 32-34 weeks of gestation.
Keyphrases
- single cell
- gestational age
- pregnancy outcomes
- rna seq
- birth weight
- early onset
- preterm infants
- polycystic ovary syndrome
- mass spectrometry
- genome wide
- type diabetes
- gene expression
- high throughput
- stem cells
- cell therapy
- high resolution
- adipose tissue
- binding protein
- skeletal muscle
- weight loss
- insulin resistance
- current status
- liquid chromatography
- breast cancer risk